Atlas
Back to RCM
Founder / Operator·RCM

Akash Magoon

Co-Founder and Chief Executive Officer at Adonis

New York, NY

AM
LinkedIn
Why they matter

Repeat healthcare-tech founder running one of the fastest-growing AI RCM platforms, with $95M+ raised, 4x 2025 revenue growth, and firsthand visibility into provider revenue-cycle pain.

Background

Akash Magoon is Co-Founder and CEO of Adonis, a New York-based AI orchestration platform for healthcare revenue cycle management he founded in 2022 with his brother Aman. Previously he co-founded insurtech Nayya in 2019, serving as CTO, and was named to the Forbes 30 Under 30 list in 2022. He has raised over $95 million for Adonis across three rounds from investors including Quadrille Capital, Point72, and General Catalyst.

Notable deals

  • 2026
    Raised $40M Series C for Adonis led by Quadrille Capital, bringing total funding past $95M after 4x revenue growth in 2025
  • 2024
    Raised $31M Series B for Adonis led by Point72 Private Investments to expand AI-driven revenue recovery for providers
  • 2023
    Raised $17.3M Series A for Adonis led by General Catalyst, one year after founding the company
  • 2022
    Named to Forbes 30 Under 30 as co-founder and CTO of insurtech Nayya

Call-prep brief

Background

  • Co-Founder & CEO of Adonis (founded 2022, NYC) with his brother Aman Magoon; previously co-founded insurtech Nayya (2019) as CTO. Forbes 30 Under 30 (2022), University of Maryland '18, earlier stints at AWS and Enigma.
  • Has raised $95M+ for Adonis: $17.3M Series A (General Catalyst, 2023), $31M Series B (Point72, 2024), $40M Series C (Quadrille Capital, March 2026).

Current focus

  • Scaling Adonis's AI orchestration platform across the full revenue cycle, eligibility, claims, denials, appeals, and moving upmarket from practices into health systems.
  • Reported 4x revenue growth in 2025 with net retention above 130%.

What they care about

  • Structural RCM problems: workforce shortages, rising denial rates, underpayments. Positions Adonis as automation that recovers revenue providers are owed, framed around customer outcomes and patient experience.

Recent moves

  • Closed the $40M Series C in March 2026; expanding the New York team and pushing deeper into AI-driven denials management.

Potential sensitivities

  • Well-capitalized and growing fast, so unlikely to engage on acquisition framing; competitive RCM-AI landscape means he may guard pipeline and product-roadmap detail. Nayya history is public but he has fully moved on.

Questions to ask

  • Which RCM subsegments (denials, eligibility, underpayments) show the strongest willingness to pay, and where is ROI hardest to prove?
  • How do health-system sales cycles and integration burdens differ from the practice segment Adonis started in?
  • Where does he see consolidation coming in RCM, legacy outsourcers acquiring AI, or AI-native platforms displacing them?

Outreach draft

Subject
AI in revenue cycle, your perspective
Hi Akash, Congratulations on the Series C, the growth Adonis has posted since 2022 stands out even in a crowded RCM field. I'm on the investment team at a private equity firm evaluating opportunities across healthcare revenue-cycle software and services, and we're forming a view on where AI-native platforms will displace legacy RCM vendors versus augment them. Your vantage point as a repeat founder who has built in both benefits and revenue cycle would be genuinely valuable. Would you be open to a 30-minute call in the next couple of weeks? Happy to share our thesis and where we see the market heading. Best, [NAME]

Linked companies

Sources